An Escherichia coli O157-Specific Engineered Pyocin Prevents and Ameliorates Infection by E. coli O157:H7 in an Animal Model of Diarrheal Disease
An Escherichia coli O157-Specific Engineered Pyocin Prevents and Ameliorates Infection by E. coli O157:H7 in an Animal Model of Diarrheal Disease
复制标题
DOI：
10.1128/aac.05031-11
复制
发表时间：
2011-12-01
影响因子：
4.9
通讯作者：
Waldor, Matthew K.
中科院分区：
文献类型：
--
作者：
Ritchie, Jennifer M.;Greenwich, Jennifer L.;Waldor, Matthew K.
AvR2-V10.3是一种工程化的r型脓毒素，可特异性杀死大肠杆菌O157，这是一种肠道病原体，是食源性腹泻病的主要原因。需要新的治疗方法来对抗大肠杆菌O157，因为目前可用的抗生素会加剧感染的后果。我们在此表明，无论是在暴露后预防方案中还是在症状出现后，口服AvR2-V10.3都可以预防或改善感染幼兔模型中大肠杆菌O157: h7诱导的腹泻和肠道炎症。值得注意的是，给药AvR2-V10.3也减少了该病原体的细菌携带和粪便脱落。我们的研究结果支持进一步开发病原体特异性r型脓毒蛋白作为治疗肠道感染的一种方法。
AvR2-V10.3 is an engineered R-type pyocin that specifically kills Escherichia coli O157, an enteric pathogen that is a major cause of food-borne diarrheal disease. New therapeutics to counteract E. coli O157 are needed, as currently available antibiotics can exacerbate the consequences of infection. We show here that orogastric administration of AvR2-V10.3 can prevent or ameliorate E. coli O157:H7-induced diarrhea and intestinal inflammation in an infant rabbit model of infection when the compound is administered either in a postexposure prophylactic regimen or after the onset of symptoms. Notably, administration of AvR2-V10.3 also reduces bacterial carriage and fecal shedding of this pathogen. Our findings support the further development of pathogen-specific R-type pyocins as a way to treat enteric infections.